Glenn Goddard - Jan 1, 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: EVP, Chief Financial Officer
Signature: James Basta, attorney-in-fact
Stock symbol: NTLA
Transactions as of: Jan 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/4/2023, 07:29 PM
Previous filing: Mar 4, 2022
Next filing: Jan 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Options Exercise		+3.06K	+20.73%		17.8K	Jan 1, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Restricted Stock Unit	Options Exercise	$0	-3.06K	-33.33%	$0.00	6.13K	Jan 1, 2023	Common Stock	3.06K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.

Content

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

On March 3, 2021, the reporting person was granted 12,250 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.